FDA OKs Tesaro’s ni­ra­parib for ovar­i­an can­cer, hand­ing the biotech a big win on the la­bel


The FDA has wast­ed no time in giv­ing Tesaro $TSRO a broad ap­proval for the use of its PARP drug ni­ra­parib, which will now be mar­ket­ed as Ze­ju­la as a main­te­nance ther­a­py for re­cur­rent ovar­i­an can­cer.

The OK and the la­bel that came with it rep­re­sents a set­back for Myr­i­ad Ge­net­ics $MYGN, which had ar­gued that its com­pan­ion di­ag­nos­tic would be need­ed to iden­ti­fy a spe­cif­ic group of ovar­i­an can­cer pa­tients with a bio­mark­er in­di­cat­ing that they would most like­ly ben­e­fit. But reg­u­la­tors blew past any di­ag­nos­tic qual­i­fi­ca­tion in giv­ing Tesaro the la­bel that it was look­ing for, vin­di­cat­ing CEO Lon­nie Moul­der’s vow that he could get an OK aimed at a large seg­ment of the mar­ket.

Tesaro had ar­gued that the ef­fi­ca­cy da­ta for ni­ra­parib qual­i­fied for an ap­proval for use in pa­tients who are ei­ther HRD pos­i­tive or HRD neg­a­tive. But they were op­posed by a part­ner who had a sol­id busi­ness case for ar­gu­ing that the drug should be re­served for pa­tients who would be most like­ly to ben­e­fit.

In the end, though, Tesaro is left with a big boast in its fa­vor: “Ze­ju­la is the on­ly PARP in­hibitor that has demon­strat­ed a clin­i­cal­ly mean­ing­ful in­crease in pro­gres­sion-free sur­vival (PFS) in women with re­cur­rent ovar­i­an can­cer, re­gard­less of BR­CA mu­ta­tion or bio­mark­er sta­tus.”

The OK al­so helps po­si­tion Tesaro against As­traZeneca, which just de­liv­ered stel­lar Phase III da­ta on its PARP Lyn­parza. Clo­vis, mean­while, gained an ap­proval for its PARP Rubra­ca late last year as a treat­ment for BR­CA-mu­tat­ed ovar­i­an can­cer that had proved re­sis­tant to at least two pri­or ther­a­pies.

It’s a trans­for­ma­tion­al mo­ment for Tesaro. Its drug was list­ed by Eval­u­atePhar­ma as one of the top drugs in the in­dus­try’s pipeline this year, with peak sales ex­pec­ta­tions hov­er­ing close to $2 bil­lion a year. And its stock climbed about 6% in af­ter-mar­ket trad­ing.

The ap­proval came months ahead of the FDA’s PDU­FA dead­line in June, in­di­cat­ing its in­ter­est and un­der­stand­ing of the field.

Mary Lynne Hed­ley, Tesaro

Ze­ju­la’s la­bel notes that it is in­di­cat­ed for the main­te­nance treat­ment of adult pa­tients with re­cur­rent ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who are in a com­plete or par­tial re­sponse to plat­inum-based chemother­a­py. And Tesaro im­me­di­ate­ly fol­lowed the news of the OK with plans to open up on the R&D pro­gram for the drug.

“Based on the un­prece­dent­ed re­sults of the NO­VA tri­al in women with re­cur­rent ovar­i­an can­cer, we pre­vi­ous­ly an­nounced the ex­pan­sion and re­fine­ment of our PRI­MA and QUADRA tri­als to in­clude a broad pa­tient pop­u­la­tion, and in the case of PRI­MA, elim­i­nat­ed the en­roll­ment re­quire­ment for a bio­mark­er se­lect­ed tu­mor. With the ap­proval of ZE­JU­LA in hand, we will now be­gin to ex­e­cute on our plans to pur­sue po­ten­tial­ly trans­for­ma­tion­al ap­pli­ca­tions of ni­ra­parib in a broad range of metasta­t­ic can­cer in­di­ca­tions,” said Mary Lynne Hed­ley, pres­i­dent and COO of TESARO. “We plan to ex­pand our first-line ovar­i­an can­cer strat­e­gy to in­clude a com­bi­na­tion study that as­sess­es the po­ten­tial ben­e­fit of ni­ra­parib plus an an­ti-PD-1 an­ti­body in the main­te­nance set­ting and ini­ti­ate a clin­i­cal study of ni­ra­parib in com­bi­na­tion with be­va­cizum­ab in pa­tients with a first re­cur­rence of ovar­i­an can­cer, with an in­tent to re­place chemother­a­py in this set­ting. We re­main strong­ly com­mit­ted to study­ing ni­ra­parib in the breast can­cer set­ting and al­so ex­pect to ini­ti­ate a new tri­al of ni­ra­parib in com­bi­na­tion with an an­ti-PD-1 an­ti­body in women with metasta­t­ic triple-neg­a­tive breast can­cer. Fi­nal­ly, our goal to move ni­ra­parib in­to in­di­ca­tions be­yond ovar­i­an and breast can­cers en­com­pass­es plans to ini­ti­ate a reg­is­tra­tion strat­e­gy for the first-line treat­ment of pa­tients with metasta­t­ic non-small cell lung can­cer that in­cludes a phase 2 tri­al of ni­ra­parib in com­bi­na­tion with an an­ti-PD-1 an­ti­body in pa­tients, re­gard­less of PDL-1 tu­mor ex­pres­sion, and a phase 3 tri­al of ni­ra­parib in com­bi­na­tion with an an­ti-PD-1 an­ti­body in pa­tients with high lev­els of PDL-1 tu­mor ex­pres­sion.”

5AM Ven­tures: Fu­el­ing the Next Gen­er­a­tion of In­no­va­tors

By RBC Capital Markets
With Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures

Key Points

Prescription Digital Therapeutics, cell therapy technologies, and in silico medicines will be a vital part of future treatment modalities.
Unlocking the potential of the microbiome could be the missing link to better disease diagnosis.
Growing links between academia, industry, and venture capital are spinning out more innovative biotech companies.
Biotech is now seen by investors as a growth space as well as a safe haven, fuelling the recent IPO boom.

Biohaven CEO Vlad Coric (Photo Credit: Andrew Venditti)

Pssst: That big Bio­haven Alzheimer's study? It was a bust. Even the sub­group analy­sis ex­ecs tout­ed was a flop

You know it’s bad when a biopharma player plucks out a subgroup analysis for a positive take — even though it was way off the statistical mark for success, like everything else.

So it was for Biohaven $BHVN on MLK Monday, as the biotech reported on the holiday that their Phase II/III Alzheimer’s study for troriluzole flunked both co-primary endpoints as well as a key biomarker analysis.

The drug — a revised version of the ALS drug riluzole designed to regulate glutamate — did not “statistically differentiate” from placebo on the Alzheimer’s Disease Assessment Scale-Cognitive Subscale 11 (ADAS-cog) and the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB).  The “hippocampal volume” assessment by MRI also failed to distinguish itself from placebo for all patients fitting the mild-to-moderate disease profile they had established for the study.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

News brief­ing: Ve­rastem CMO ex­its two weeks af­ter join­ing com­pa­ny; Ther­mo Fish­er inks $550M M&A deal

Two weeks after joining Verastem Oncology as chief medical officer, Frank Neumann is leaving the company for another job.

Neumann had joined Verastem after leaving bluebird bio, which surprisingly split into two companies last week, one in oncology and one in rare diseases. It’s not yet clear to where Neumann is headed next, but he noted in a statement that Verastem’s data and strategy were “truly exciting.”

FDA hits the brakes on His­to­gen's knee car­ti­lage ther­a­py, ask­ing for more in­fo on man­u­fac­tur­ing process

A month after filing the IND application for its human extracellular matrix designed to regenerate knee cartilage, Histogen has hit a roadblock.

The FDA on Tuesday verbally notified the San Diego-based biotech that it was placing a clinical hold on the planned Phase I/II clinical trial of HST-003 due to pending CMC information and additional questions needed to complete their review.

Histogen had planned to test the safety and efficacy of implanting hECM within microfracture interstices and related cartilage defects to regenerate that cartilage in conjunction with a microfracture procedure. The company said in a press release that it expects to receive written notice of the clinical hold from the FDA by Feb 12.

Andrew Allen, Gritstone CEO (Gritstone via website)

Grit­stone con­tin­ues Covid-19 push with deal to de­vel­op 'self-am­pli­fy­ing RNA' vac­cines, as shares con­tin­ue bal­loon­ing

Gritstone Oncology has had a big week, and it’s only Wednesday.

On Tuesday, the biotech revealed plans to start clinical testing of an experimental Covid-19 vaccine — in tandem with NIAID — that can also target other coronaviruses, with the goal of preventing future pandemics should SARS-CoV-2 prove difficult to cure with current vaccines. Then, on Wednesday morning, Gritstone licensed lipid nanoparticle technology from Genevant Sciences to develop what it’s calling “self-amplifying RNA vaccines” against Covid-19.

Artist rendering of the Assembly Square site in Somerville, MA (BioMed Realty)

Bio­Med Re­al­ty snaps up in­no­va­tion cam­pus site with­in earshot of pricey and bustling Boston biotech hub

On the short list of the premier biotech hubs in the world, the Boston area has transformed into a home for innovation — and ridiculously high rent. Now, a real estate firm is seeking tenants for a major site in neighboring Somerville with more than enough elbow room.

Snapped up by BioMed Realty, the land — which consists of an existing 162,000 square-foot office building and a 7.5 acre site — will serve as an “innovation space” for a variety of research, technology and life science tenants, the real estate company said in a press release. Financial terms weren’t disclosed.

Hal Barron, GSK R&D chief (GSK via YouTube)

Glax­o­SmithK­line's $4B bis­pe­cif­ic can­cer drug al­liance with Mer­ck KGaA hit by big set­back with a PhI­II fail­ure on NSCLC

Close to 2 years ago, GSK’s R&D team eagerly agreed to pay up to $4 billion-plus to ally itself with Merck KGaA on a mid-stage bispecific called bintrafusp alfa, which intrigued them with the combination of a TGF-β trap with the anti-PD-L1 mechanism in one fusion protein.

But today the German pharma company says that their lead study on lung cancer was a bust, as independent monitors said there was no reason to believe that the experimental drug — targeting PD-L1/TGF-Beta — could beat Keytruda.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 98,200+ biopharma pros reading Endpoints daily — and it's free.

Union members strike in France, AP Images

Paul Hud­son faces down French unions in fight to re­struc­ture Sanofi

Sanofi CEO Paul Hudson is facing a familiar adversary in his efforts to cut up to 1,680 jobs from the French pharma giant: French unions.

Around 200 union members staged a one-day strike Tuesday at Sanofi’s main Covid-19 vaccine plant in Marcy-l’Étoile to protest the cuts, The Associated Press reported, with other members joining at other facilities across the country.

France’s finance minister Bruno Le Maire, meanwhile, went on French radio twice this week to talk about the company. On Monday, per Reuters, he told RTL that Sanofi would not close any plants or lay off any employees in the restructuring. But on Wednesday morning, he re-emerged on BFM and said he would like three things from the drugmaker, including confirmation that there will be no site closures and layoffs.

Janet Woodcock and Joshua Sharfstein (AP, Images)

Poll: Should Joshua Sharf­stein or Janet Wood­cock lead the FDA from here?

It’s time for a new FDA commissioner to come on board, a rite of passage for Joe Biden’s administration that should help seal the new president’s rep on seeking out the experts to lead the government over the next 4 years.

As of now, the competition for the top job appears to have narrowed down to 2 people: The longtime CDER chief Janet Woodcock and Joshua Sharfstein, the former principal deputy at the FDA under Peggy Hamburg. Both were appointed by Barack Obama.